Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

This study is testing whether adding a low-intensity ultrasound device (a type of sound wave therapy) to the standard post-surgery chemotherapy regimen for people with newly diagnosed glioblastoma (an aggressive brain tumor) improves survival. The ultrasound is delivered through a wearable device and is meant to disrupt tumor cell division. **You may be eligible if...** - You are between 18 and 80 years old - You have been newly diagnosed with glioblastoma confirmed by biopsy (WHO 2021 criteria, without IDH mutation) - You have already undergone tumor removal surgery and completed the standard combination of radiation and chemotherapy (temozolomide) - Your cancer has not progressed since completing chemoradiation - You are in reasonably good health and your blood counts and organ function are adequate **You may NOT be eligible if...** - You only had a biopsy (not actual tumor removal surgery) - You did not complete at least 90% of your planned radiation and 66% of your chemotherapy doses - You still have significant side effects from your chemoradiation that have not resolved - You are pregnant or breastfeeding - You have an active serious infection or other condition that would make treatment unsafe Talk to your doctor to see if this trial is right for you.